AB0494 Early Clinical Experiences with Belimumab in Polish Patients with Systemic Lupus Erythematosus

• Published in: Annals of the rheumatic diseases Vol. 73; no. Suppl 2; p. 970
• Main Authors: Majdan, M., Kucharz, E.J., Jeka, S., Sierakowski, S., Leszczyński, P., Tł ustochowicz, W., Olesińska, M., Gł uszko, P., Krężelok, M., Suszek, D., Kopeć-Mędrek, M., Kolossa, K., Domysławska, I., Pawlak-Buś, K., Kur-Zalewska, J., Felis-Giemza, A., Zielińska, A., Brużewicz, S., Skoczylas, K.
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier Limited 01.06.2014

Background Belimumab is a monoclonal antibody, inhibitor of soluble B-cell activating factor, that is used in the adjuvant treatment of adult patients with active seropositive systemic lupus erythematosus (SLE) [1]. Belimumab was approved in Poland in 2011. Objectives To analyze the influence of bel...